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Radiofrequency ablation (RFA) has changed the treatment strategy of hepatocellular carcinoma. Although RFA is usually applied for the treatment of small
(3 cm) hepatocellular carcinomas, the combination with hepatic arterial chemoembolization has expanded the use of RFA to larger tumors. Reﬁnements
have lessened complications, leading to better prognosis even in the longer term.
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Radiofrequency ablation (RFA) has been applied to clinical
practice since the early 1990s and rapidly disseminated to become
the ﬁrst-choice locoregional treatment. Less than a decade after its
introduction, RFA was resulting in a higher rate of complete ne-
crosis and required fewer treatment sessions than percutaneous
ethanol injection (PEI) in small (3 cm) hepatocellular carcinoma
(HCC) lesions.1 However, at about the same time, the diminishing
effectiveness of RFA in achieving tumor necrosis with increasing
tumor size was apparent.2 In addition to tumor size, blood ﬂow and
tumor location affect the antitumor effect.3,4
Attempts have been made to overcome these limitations and
increase the antitumor effect.5–13 Furthermore, some measures
have been developed to avoid RFA-related complications, resulting
in marked improvement in the safety of liver RFA.14,15 These efforts
have lead to improved therapeutic outcomes, and 10-year survival
rates have been reported recently.16,17
The current status of liver RFA is reviewed in this manuscript.
Indication for liver RFA
The need for liver RFA is generally determined by taking into
account patients’ performance status, liver function, and tumor
background. Based on the Barcelona Clinic Liver Cancer staging
system, RFA is applied for the treatment of patients having very
early (Stage 0) and early stage (Stage A) HCC. Patients with per-
formance status of 0, Child-Pugh class A or B liver proﬁle, and three
or fewer HCC nodules 3 cm are indicated for RFA.18 However,
these indication criteria also point out the limitation of RFA. Small
ablation zone size obtained in a single treatment session limits theDepartment of Interventional Radiology, Mie University School of Medicine, Tsu, Mie, Japan
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http://dx.doi.org/10.1016/j.gii.2014.04.002indication of RFA. RFA is applied in <30–40% of HCC patients in
Europe and the USA, and 30.6% in Japan.18,19 According to the report
from the Liver Cancer Study Group of Japan, HCCs were found at a
maximum size of 3 cm and 3.1–5 cm in 57.5% and 21.5% of HCC
patients, respectively.19 If the indication for RFA is expanded to
include a maximum size up to 5 cm, more HCC patients can beneﬁt
from RFA.
Exclusion criteria were determined by taking into account
complications. Hemorrhage is one of the most frequent severe
complications. Patients with abnormal coagulability, even after its
correction, are usually excluded. In general, platelet counts <40–
50  109/L and/or international normalized ratio exceeding 1.5 are
benchmarks of abnormal coagulability.
When the targeting tumor is adjacent to the critical organs, such
as the gastrointestinal (GI) tract, the risk of collateral damage is
high. The risk of liver abscess also becomes higher when there is a
past history of biliary surgery.20
Local therapeutic effect
Local tumor control is important in HCC patients because it is
signiﬁcantly linked with survival.21 Local tumor progression is
usually evaluated by contrast-enhanced computed tomography or
magnetic resonance imaging. Livraghi et al evaluated the initial
therapeutic effect of RFA on HCC based on tumor size by evaluating
the disappearance of tumor enhancement following RFA.1,2 The
anticancer effect was stronger as the tumor size became smaller.
Tumor enhancement completely disappeared in 90% of small HCCs
(3 cm), 60% of medium-sized HCCs (3.1–5 cm), and 24% of large
HCCs (>5 cm; Table 1).1,2 The local tumor progression rate has been
reported to be 2.4–19.5% at 3 years when the maximum tumor sizeol of Medicine, Edobashi, 2-174, Tsu, Mie 514-8507, Japan.
vier. Open access under CC BY-NC-ND license.
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Gastrointestinal Intervention 2014 3(1), 35–3936is  3 cm (Table 1).6,17,22,23 Inﬁltrating tumor morphology, previous
treatment history, subphrenic tumor location, vicinity to the ves-
sels, and ablative margin may signiﬁcantly worsen local tumor
progression.6,22–25
Some of these limitations can be overcome. When the tumor is
in the liver dome, it is sometimes difﬁcult to depict the whole
tumor by ultrasonography, and almost half of the subphrenic tu-
mors recur at 3 years after RFA.26 The usefulness of artiﬁcial pleural
effusion, artiﬁcial ascites, and real-time virtual sonography has
been reported to depict tumors that are invisible by conventional
ultrasonography.27–29 By contrast, there is no blind spot when using
computed tomography as an image guide; in particular, iodized-oil
accumulates in the tumor after chemoembolization (Fig. 1).30 The
local tumor progression rate is as low as 3% at 5 years after the
combination therapy of RFA and chemoembolization.30
The ablative zone is limited by blood ﬂow (heat-sink effect),
causing a small ablative margin.3–9,31 An ablative margin of at least
5 mm is required to avoid local tumor progression, because mi-
crosatellite lesions are frequently present surrounding the HCC
nodule.25 Sasaki et al measured the distance of microsatellites from
the main HCC nodule in resected specimens.32 Most of the micro-
satellite lesions were present within 5mm of themain tumor when
the tumor size was 25 mm.32 The overall survival rate of patients
with a microsatellite distance exceeding 5 mmwas lower than that
of patients with a microsatellite distance < 5 mm.32
Overlapping insertions of RF electrodes sometimes fail to pro-
duce large ablation zones relative to the number of ablations.25,33 A
decrease in blood ﬂow in the liver causes expansion of the ablative
zone size.5,31,34 Balloon occlusion of the hepatic artery, chemo-
embolization of the hepatic artery, portal venous embolization, and
hepatic venous balloon occlusion have been combined with RFA in
an attempt to expand the ablative zone size.5–9 RFA following
chemoembolization is the most popular combination therapy
among these options (Fig. 1).
Takaki et al performed RFA following chemoembolization and
reported a 5-year local tumor progression rate of 8% in patients
with small (3 cm) HCCs, 25% in those with HCCs measuring 3.1–
5 cm, and 32% in those with HCCs measuring 5.1–10 cm maximum
diameter.6,8 Morimoto et al compared the local tumor progression
in HCC lesions measuring 3.1–5 cm between RFA alone and com-
bination of RFA and chemoembolization.35 The 3-year local tumor
progression rate was signiﬁcantly lower in combination therapy
than RFA alone (6% vs. 39%, P ¼ 0.012).
Recently, microwave ablation has emerged as a valuable alter-
native to RFA in the treatment of hepatic malignancies.36 Micro-
wave ablation is a promising heat-based thermal ablation modality
that has particular applicability in treating hepatic malignancies;
the ability to generate very high temperatures in a very short time
can potentially improve treatment efﬁciency and larger ablation
zones with less heat-sink effect.36 Comparison of local tumor pro-
gression between RFA and microwave ablation is required.
Survival after RFA
Superiority of RFA to PEI in prolonging patient survival has been
shown in a randomized controlled trial.37 The 3-year survival rates
were 48–67% following PEI and 63–81% following RFA. Chen et al
performed a randomized control trial between RFA and hepatec-
tomy in patients who had HCC 5 cm, and found the same overall
and recurrence-free survival between the two patient groups.38
Combination therapy of RFA and chemoembolization also pro-
vides HCC patients the same survival as surgical intervention does.
Yamakado et al retrospectively compared overall and recurrence-
free survivals between this combination therapy and hepatec-
tomy in Child-Pugh grade-A patients who had HCC lesions within
Fig. 1. Details of one case. (A) A hepatocellular carcinoma measuring 2 cm was located in the liver dome on contrast enhanced computed tomography (CT) study (arrow). (B)
Selective chemoembolization was performed before radiofrequency (RF) ablation. (C) RF electrodes were placed in the center of the tumor under the real-time CT-ﬂuoroscopic
guidance, and RF energy was applied. (D) Contrast-enhanced CT images showed clear ablative margin surrounding the tumor in which iodized-oil accumulated 3 days after RF
ablation.
Koichiro Yamakado et al. / RFA for Hepatocellular Carcinoma 37the Milan criteria.7 There were no signiﬁcant differences found in
the 5-year overall survival rate (75% vs. 81%) or recurrence-free
survival rate (27% vs. 26%). Combination therapy of RFA and che-
moembolization is useful in treating HCC nodules larger than 5 cm.
Takaki et al performed combination therapy in 20 patients who had
three or fewer HCC nodules with a maximum diameter of 5.1–
10 cm and reported a 5-year survival rate of 41%, which was almost
equal to that following hepatectomy (Table 1).8 The 5-year survival
rates following hepatectomy was reported as 43.8% in patients who
had HCC nodules with maximum diameter 5.1–10 cm.39
Recently, survival rates up to 10 years have started to be re-
ported.16,17 Shiina et al treated 1170 patients by RFA and reported 5-
and 10-year survival rate of 60.2% and 27.3%, respectively (Table
1).16 They combined chemoembolization in patients with four or
more tumors or those with even one tumor larger than 3 cm. Age,
hepatitis C, Child–Pugh grade, tumor diameter, tumor number, des-
g-carboxy-prothrombin, and lectin-reactive a-fetoprotein level ere
signiﬁcant prognostic factors. Fujimori et al performed combina-
tion therapy of RFA and chemoembolization in 277 naïve HCC pa-
tients, and reported a 5- and 10-year survival rate of 56.3% and
23.5%, respectively (Table 1).17 Those results were almost compa-
rable to those following hepatectomy.
Complications
Livraghi et al reported complications in 2,320 patients with
3,554 liver tumors.40 The mortality rate was 0.3%. The causes of
death were bowel perforation, peritonitis, tumor rupture, and liver
failure due to biliary stricture. The major complication rate was2.2%. Themost frequent major complications were hemorrhage and
tumor seeding, with an incidence of 0.5% each, followed by liver
abscess (0.3%), bowel perforation (0.2%), hemothorax (0.1%), and
liver failure (0.1%). An increased number of RF sessions were related
to a higher rate of major complications (P < 0.01), whereas the
number of complications was not signiﬁcantly different when
tumor size or electrode type were compared. Minor complications
that did not require treatment developed in <5% of patients. Takaki
et al41 evaluated complications following 1500 treatment sessions
of combination of RFA and chemoembolization, and reported the
same mortality (0.1%) and major complication (2.8%) rates as those
reported by Livrghi et al.40 The content of complications were also
same between the two studies. From these studies, hemorrhage
and bowel perforation are most frequent severe complications.
To prevent hemorrhagic complications, patients with abnormal
coagulability should be excluded as mentioned in the indication
section. Combined use of chemoembolization is useful in avoiding
hemorrhagic complications.41
The liver is sometimes adjacent to the stomach, ascending colon,
and duodenum. When the liver tumor is close to the GI tract, the GI
tract should be moved away from the tumor to avoid collateral
damage from RFA. Based on empirical observations, most tumors
can bemoved away from the GI tract by changing the patient’s body
position, injecting saline solution into the peritoneal cavity, or
aspirating intrabowel air and ﬂuid. If the liver neoplasms could not
be moved away from the GI tract by the above measures, the
placement of a balloon between the tumor and the GI tract appears
to be a practical, safe, and effective technique for separating the
tumor from the adjacent bowel.14 Recently, the usefulness of
Fig. 2. Details of another case. (A) Hepatocellular carcinoma measuring 1.5 cm recurred in the liver stump after left lobectomy (arrow). The tumor was adjacent to the stomach. (B)
Chemoembolization was done before radiofrequency ablation (RFA). An RF electrode (white arrow) was placed in the tumor under the real-time computed tomography ﬂuoroscopic
guide after the tumor was separated from the stomach by injecting hyaluronic acid gel (black arrow) between the tumor and the stomach. (C) The tumor was completely ablated on
contrast-enhanced computed tomography images acquired after RFA. There were no complications related to the procedures.
Gastrointestinal Intervention 2014 3(1), 35–3938hyaluronic acid gel injection between the tumor and the GI tract in
separating the bowel from the tumor has been reported (Fig. 2).15
Conclusions
Development of both technique and technology of RFA has
expanded the indication of RFA and improved local control of HCC.
Development of techniques and accumulation of knowledge to
prevent complications have established the safety of hepatic RFA.
The good local tumor control and safety provide a longer survival to
patients with HCCs.
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